$0.80
0.03% today
Nasdaq, Aug 22, 10:19 pm CET
ISIN
US54303L1044
Symbol
LGVN

Longeveron Inc - Ordinary Shares - Class A Stock price

$0.80
-0.87 52.11% 1M
-0.71 47.03% 6M
-0.93 53.77% YTD
-1.83 69.59% 1Y
-50.60 98.44% 3Y
-99.20 99.20% 5Y
-99.20 99.20% 10Y
-99.20 99.20% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
-0.00 0.03%
ISIN
US54303L1044
Symbol
LGVN
Industry

Key metrics

Basic
Market capitalization
$16.6m
Enterprise Value
$2.3m
Net debt
positive
Cash
$14.3m
Shares outstanding
15.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.5 | 9.4
EV/Sales
1.0 | 1.3
EV/FCF
negative
P/B
1.0
Financial Health
Equity Ratio
85.6%
Return on Equity
-112.5%
ROCE
-97.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$2.2m | $1.8m
EBITDA
$-16.5m | -
EBIT
$-17.6m | $-23.7m
Net Income
$-25.6m | $-20.0m
Free Cash Flow
$-16.6m
Growth (TTM | estimate)
Revenue
127.6% | -26.3%
EBITDA
16.5% | -
EBIT
14.9% | -43.7%
Net Income
-18.3% | 19.0%
Free Cash Flow
1.8%
Margin (TTM | estimate)
Gross
82.3%
EBITDA
-740.9% | -
EBIT
-791.5%
Net
-1,149.4% | -1,132.3%
Free Cash Flow
-744.9%
More
EPS
$-1.7
FCF per Share
$-1.1
Short interest
4.1%
Employees
25
Rev per Employee
$100.0k
Show more

Is Longeveron Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Longeveron Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Longeveron Inc - Ordinary Shares - Class A forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Longeveron Inc - Ordinary Shares - Class A forecast:

Buy
89%
Hold
11%

Financial data from Longeveron Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2.23 2.23
128% 128%
100%
- Direct Costs 0.39 0.39
22% 22%
17%
1.83 1.83
289% 289%
82%
- Selling and Administrative Expenses 11 11
11% 11%
494%
- Research and Development Expense 8.43 8.43
1% 1%
378%
-16 -16
17% 17%
-739%
- Depreciation and Amortization 1.13 1.13
18% 18%
51%
EBIT (Operating Income) EBIT -18 -18
15% 15%
-790%
Net Profit -26 -26
18% 18%
-1,147%

In millions USD.

Don't miss a Thing! We will send you all news about Longeveron Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Longeveron Inc - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
2 days ago
MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 in New York City.
Neutral
Seeking Alpha
9 days ago
Longeveron Inc. (NASDAQ:LGVN ) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Devin Blass - CTO & Senior VP of Chemistry, Manufacturing, and Controls Joshua Michael Hare - Co-Founder, Chief Science Officer & Chairman Lisa A. Locklear - CFO, Executive VP & Treasurer Mohamed Wa'el Ahmed Hashad - CEO & Director Nataliya Agafonova - Chief Medical Officer Conference...
Neutral
GlobeNewsWire
9 days ago
MIAMI, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today reported financial results for the quarter ended June 30, 2025 and provided a business update.
More Longeveron Inc - Ordinary Shares - Class A News

Company Profile

Longeveron LLC is a clinical stage biotechnology company that engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. The company was founded by Joshua M. Hare and Donald M. Soffers in October 9, 2014 and is headquartered in Miami, FL.

Head office United States
CEO Mohamed Hashad
Employees 25
Founded 2014
Website www.longeveron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today